Log in to your Inderes Free account to see all free content on this page.
Xintela
0.22 SEK
-0.45 %
Less than 1K followers
XINT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Xintela
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.8 | 1.1 | 4.2 | 0.1 | 0.9 | 0.9 | 0.4 | 2.3 |
| EBITDA | -7.4 | -11.3 | -39.5 | -10.1 | -11.5 | -9.3 | -15.4 | -46.1 |
| EBIT | -7.4 | -10.9 | -39.5 | -10.1 | -11.5 | -9.5 | -15.6 | -46.7 |
| EBIT-% | -261.3 % | -990.0 % | -934.8 % | -7,207.1 % | -1,325.3 % | -1,107.5 % | -3,758.1 % | -2,045.7 % |
| Profit before taxes | -8.1 | -11.7 | -41.5 | -10.7 | -12.1 | -10.0 | -17.3 | -50.2 |
| Net income | -7.8 | -10.4 | -39.2 | -10.4 | -12.0 | -9.5 | -16.7 | -48.6 |
Login required
This content is only available for logged in users